TrialHuman vaccines & immunotherapeutics2013

Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules.

Timo Vesikari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.